Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Arteriocyte, a clinical stage biotechnology company, has received a fast track Phase I/II small business innovation research grant award from the National Heart, Lung, and Blood Institute, of the National Institutes of Health.
Subscribe to our email newsletter
The grant award is the first installment of the combined $2.5 million grant from the National Institutes of Health (NIH) to clinically evaluate the therapeutic feasibility of treating critical limb ischemia with the company’s expanded human umbilical cord blood derived stem cell therapy (ALO212) using Arteriocyte’s proprietary Nanex cell expansion technology.
The company’s Nanex technology provides for a rapid ex-vivo culturing of hemangioblasts, an early progenitor cell shown to have potential in improving perfusion in ischemic tissues.
The NIH award is said to represent an important step in the company’s commercialization of ALO212, its second stem cell pipeline product candidate, transitioning to clinical stage evaluation. The balance of the funding from the National Heart, Lung, and Blood Institute is expected to be awarded, contingent on successful completion of the Phase I work.